Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upadacitinib - AbbVie

Next Previous
X
Search
Drug Profile

Upadacitinib - AbbVie

Alternative Names: ABT-494; RINVOQ; Upadacitinib extended release - Abbvie; Upadacitinib modified release - Abbvie; Upadacitinib prolonged release - Abbvie; Upadacitinib tartrate; Upadicitinib hemihydrate - Abbvie

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Registered Non-radiographic axial spondyloarthritis
  • Phase III Alopecia areata; Giant cell arteritis; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Systemic lupus erythematosus; Vasculitis; Vitiligo

Most Recent Events

  • 03 May 2024 AbbVie plans a phase IIIb/IV Switch-Up trial for Atopic dermatitis (Treatment-experienced) in May 2024 (PO, Tablets) (NCT06389136)
  • 03 May 2024 Abbvie plans a phase IIIb/IV SLEEP UP trial for Atopic dermatitis (Treatment experienced) (PO, Tablet) in May 2024 (NCT06390722)
  • 25 Apr 2024 Efficacy and adverse event data from the phase IIIb/IV LEVEL-UP trial in Atopic dermatitis released by AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top